- China opens $71 bn 'swap facility' to boost markets
- Asian markets track Wall St record as Hong Kong, Shanghai stabilise
- 'Denying my potential': women at Japan's top university call out gender imbalance
- China's central bank says opens up $70.6 bn in liquidity to boost market
- Youth facing unprecedented wave of violence, UN envoy warns
- 'A casino in every kitchen': Brazil's online gambling craze
- Nobel chemistry winner sees engineered proteins solving tough problems
- Discord seen as online home for renegades
- US forecasts severe solar storm starting Thursday
- Ratan Tata: Indian mogul who built a global powerhouse
- One dead as storm Kirk tears through Spain, Portugal, France
- Indian business titan Ratan Tata dead at 86
- Fed minutes highlight divisions over rate cut decision
- Steve McQueen debuts new WWII film at London festival
- Nobel winners hope protein work will spur 'incredible' breakthroughs
- What are proteins again? Nobel-winning chemistry explained
- AI steps into science limelight with Nobel wins
- Overshooting 1.5C risks 'irreversible' climate impact: study
- Demis Hassabis, from chess prodigy to Nobel-winning AI pioneer
- Global stocks diverge as Chinese shares tumble
- Time runs out in Florida to flee Hurricane Milton
- Chad issues warning ahead of more devastating floods
- Creator's death no bar to new 'Dragon Ball' products
- Chinese stocks tumble on lack of fresh stimulus
- Trio wins chemistry Nobel for protein design, prediction
- Braving war: Lebanon's 'badass' airline defies odds
- US weighs Google breakup in landmark trial
- Chinese stocks tumble on stimulus upset, Asia tracks Wall St higher
- 7-Eleven owner confirms new takeover offer from Couche-Tard
- A US climate scientist sees hurricane Helene's devastation firsthand
- Can carbon credits help close coal plants?
- Boeing suspends negotiations with striking workers
- 7-Eleven owner's shares spike on report of new buyout offer
- Your 'local everything': what 7-Eleven buyout battle means for Japan
- AI-aided research, new materials eyed for Nobel Chemistry Prize
- The US economy is solid: Why are voters gloomy?
- Scientists sound AI alarm after winning physics Nobel
- Nobel-winning physicist 'unnerved' by AI technology he helped create
- Trump secretly sent Covid tests to Putin: Bob Woodward book
- Neural networks, machine learning? Nobel-winning AI science explained
- Boeing delivers 27 MAX jets in September despite strike
- Stock markets diverge as Hong Kong sinks, oil prices fall
- US trade gap narrowest in five months as imports slip
- Stay and 'you are going to die': Florida braces for next hurricane
- Geoffrey Hinton, soft-spoken godfather of AI
- Duo wins Physics Nobel for 'foundational' AI breakthroughs
- German 'Maddie' suspect could be free in 2025 after cleared of separate sex crimes
- China slaps provisional tariffs on EU brandy imports
- Duo wins Physics Nobel for key breakthroughs in AI
- German 'Maddie' suspect could be free soon after cleared of separate sex crimes
Pfizer eyes big drop in Covid-related revenues in 2023
After two straight years of surging sales due to Covid-19 products, Pfizer projected a steep decline in 2023 revenues as demand for vaccines and therapeutics ebbs.
The pharma giant expects about a 30 percent drop in company revenues this year as governments work off excess inventories of Pfizer's coronavirus-related products and consumer demand wanes in some markets.
Sales for the vaccine Comirnaty and the Covid-9 therapeutic Paxlovid will reach a "low point" this year before rebounding somewhat in 2024, the company said.
The hit means Pfizer expects 2023 revenues of between $67-71 billion, down about 30 percent from the 2022 level.
Pfizer's revenues rose by nearly a quarter between 2021 and 2022 after almost doubling in the prior stretch.
Pfizer expects 2024 sales of Covid products to stabilize, said Chief Executive Albert Bourla.
"Then starting in 2025 and continuing in 2026 and beyond, we expect to see an increase in Covid-19 vaccination rates, assuming the successful development and approval of a Covid-flu combination product," Bourla said in prepared remarks.
Pfizer projected that 24 percent of the US population would receive a Covid-19 vaccine in 2023, down from the 31 percent level in 2022.
But Bourla said the combined Covid/flu vaccine could bring the level in line with the current flu shot benchmark of about 50 percent of all Americans.
Pfizer expects increased uptick for its Covid therapeutic in China. The company has agreements in China with one company to import and distribute Paxlovid and with another Chinese enterprise to manufacture the drug locally.
"Pfizer shipped only tens of thousands of courses to China in fiscal 2022," Bourla said. "From December through March we expect to ship millions of courses to meet local demand."
In terms of overall fourth-quarter earnings, Pfizer reported profits of $5.0 billion, up 47 percent from the year-ago period.
Revenues rose two percent to $24.3 billion.
Pfizer said it is also hard at work on non-Covid output, planning 19 new products over an 18-month period.
Shares of Pfizer declined 0.3 percent to $43.44 in early Tuesday trade.
H.Müller--CPN